CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 Chemotherapy Foundation Symposium
Oncology Conference Multimedia
View more videos >>
Oncology Conference Articles
Immunotherapy Approval Offers New Hope in CSCC
Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.
Adjuvant Options Arrive for Melanoma
The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.
Personalized Immunotherapy Combinations on Horizon
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.
Emerging Agents, Strategies Propel Progress in Follicular Lymphoma
Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS
CAR T-Cell Therapies Moving to Outpatient Setting
The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.
Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL
The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.
FDA Approvals in Pediatric ALL and PNH, Japanese Approves Pembrolizumab in 5 Indications, and More
Treatment Goals in Refractory mCRC
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
Controversy Adds Caution to CRISPR Editing in United States
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.